Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Hemasphere. 2022 May 12;6(6):e719. doi: 10.1097/HS9.0000000000000719. eCollection 2022 Jun.

Authors

Alessandra Petrillo¹, Andrew Ip^{1

2

3}, Alexandra Della Pia^{1

4}, Sarvainder Gill¹, Joshua Zenreich³, Martin Gutierrez^{1

3}, Ann McNeill³, Tatyana Feldman^{1

2

3}, Lori A Leslie^{1

2

3}, Andre Goy^{1

2

3}

Affiliations

¹ Hackensack University Medical Center, Hackensack, NJ, USA.
² Hackensack Meridian School of Medicine, Nutley, NJ, USA.
³ John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
⁴ Ernest Mario School of Pharmacy at Rutgers University, Piscataway, NJ, USA.

No abstract available